|
|
| |
 |
Ruth Alon, Chairman of the Board |
|
Ms. Alon joined Pitango in 1998. With over 26 years of international
experience in the high-tech medical industry, Ms. Ruth Alon heads the life
sciences activities at Pitango.
Ms. Alon previously worked on Wall Street where she held senior positions
with Montgomery Securities and Kidder Peabody & Co. As a senior medical device
analyst, Ms. Alon was rated as one of the top in her field for four consecutive
years. She also managed her own independent consulting business in San
Francisco, providing broad-based services to early-stage companies and venture
capitalists in the medical devices industry.
Ms. Alon has a B.A. in Economics from the Hebrew University of Jerusalem, an
M.B.A. from Boston University, and an M.S. from the Columbia University School
of Physicians and Surgeons.
|
|
Dr. Daphna Heffetz, CEO and Director |
| |
Prior to joining TransPharma, Dr. Heffetz served as CEO and Director of Savyon
Diagnostics. Dr. Heffetz received her Ph.D. in biochemistry from the Weizmann
Institute of Science in 1991, followed by a postdoctoral fellowship in molecular
biology. She has published numerous articles in leading scientific journals, and
has been the recipient of a number of academic awards and prizes.
|
|
Yossi Gross - Director |
|
Mr. Gross is a co-founder of TransPharma, and participates and advises in the
company’s research and development activities. Mr. Gross was Vice President of
Research & Development at Elan Medical Technologies (Israel) Ltd., a subsidiary
of Elan Corporation, a world leader in advanced drug delivery systems. From 1988
to 1995, Mr. Gross directed the research and development operations of
Scientific Innovations Ltd. Between 1977 and 1985, he served in key management
positions in the Engineering Division of Israel Aircraft Industries. Mr. Gross
has over 100 patents registered in his name. He received an M.Sc. degree in
Aeronautical Engineering from the Technion - Israel Institute of Technology in
1976.
|
|
Dr. Ronit Bendori - Director |
|
Dr. Bendori joined Evergreen in mid 2000 and is a Partner. She focuses on
Evergreen’s investments in the life sciences sector. Dr. Bendori is a former
Vice President of Pharmos Ltd. and QA/QC Director of Pharmos Corporation
(NASDAQ: PARS). Dr. Bendori also held various senior positions as an expert in
technology transfer at InterPharm Ltd. (Israel) and Ares-Serono (Switzerland).
As one of its most experienced figures, Dr. Bendori is an active promoter of the
Israeli biotech industry. She is one of the founders of the Israeli
Biotechnology Organization (IBO), a management group member of the of the
Manufacturers Association of Israel, and an adviser to the Chief Scientist at
the Israeli Ministry of Industry and Trade on biotechnology issues. Dr. Bendori
has taught biotechnology in various institutions, including the Israeli Center
for Management and the Weizmann Institute of Science. She sits on the boards of
Colbar Ltd., Procognia and Transpharma, Evergreen investments that she led. Dr.
Bendori has a Ph.D. in molecular and cellular biology from the Weizmann
Institute of Science.
|
|
Dr. Mario Thomas - Director |
|
Dr. Thomas is Partner and Vice President at T2C2/Bio, a leading Canadian
Life Sciences venture capital firm, and has over 20 years of experience in the
pharmaceutical and biotechnology industries. He holds a Ph.D. in chemistry
from Université Laval in Québec City and a diploma in business administration
from École des Hautes Études Commerciales of Université de Montréal. Dr.
Thomas started his career at Johnson & Johnson Inc. in Canada in 1979 in R&D,
and then moved to marketing. He joined Burroughs Wellcome Inc. in 1987 where
he became Business Manager for the Virology and Oncology unit. In 1993, he
served as Vice President, Business Development for the therapeutic division of
BioChem Pharma. He has also been President & CEO of TerraGen Discovery Inc.
and Chairman & CEO of Entomed SA, a biotech start-up based in Strasbourg,
France.
|
|
Jason Martin – Director
|
| |
Jason Martin is Managing Director of Argonaut Private Equity, a global private
equity fund based in Tulsa, Oklahoma. Since launching Argonaut in 2002, Mr.
Martin has invested in more than 20 privately-held companies in industries as
diverse as specialty materials, telecommunications, software, drug delivery,
aviation, and consumer electronics. He currently serves as a director of Cordys
Holding (Putten, Netherlands), Memjet (Sydney, Australia), Omni Air
International (Tulsa, Oklahoma), Flash Networks (Herzliya, Israel), TransPharma
Medical (Lod, Israel), Sol-Gel Technologies (Bet Shemesh, Israel), Yulex
(Carlsbad, California), VoiceSignal (Woburn, Massachusetts), Luminus Devices
(Woburn, Massachusetts) and Midas Communication Technologies (Chennai, India). Prior to Argonaut, Mr. Martin was Managing Director of Williams
Communications, where he led more than a dozen investments in high-tech
companies. His previous experience includes senior management positions in the
telecommunications industry and managing institutional investment programs. Mr.
Martin is a graduate of Harvard College.
|
|
Larry Ellberger – Director |
|
Mr. Ellberger is a Founder and Principal of HVA, Inc. a consulting firm
specializing in business development, product acquisition and licensing, and
mergers and acquisitions for pharmaceutical, biotechnology, drug delivery, and
medical device companies. He also is a member of the Board of Directors at Omrix
Biopharmaceuticals, Inc., a NASDAQ-listed commercial-stage biopharmaceutical
company, and Avant Immunotherapeutics, a NASDAQ-listed vaccine biotechnology
company.
Most recently, Mr. Ellberger held the position of Interim CEO of PDI, Inc., a
sales and marketing service provider for pharmaceutical and biotech companies.
Prior to that, he was Senior Vice President of Corporate Development and a
member of the Board of Directors at PowderJect, a publicly-traded drug delivery
company. Previously, Mr. Ellberger held several senior positions during his 20
year tenure at American Cyanamid Company, a leading life science company. He was
also CFO and interim CEO at W.R. Grace & Co.
|
|
| |
© TransPharma Medical™ Ltd. All Rights Reserved.
updated May 2005
|
|
